Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse

Journal of Clinical Investigation

Volumn 96, Issue 3, 1995, Pages 1621-1630

  Olman, Mitchell A ^a,b,c   Mackman, Nigel ^a   Gladson, Candece L ^c   Moser, Kenneth M ^b   Loskutoff, David J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Fibrinolysis; In situ hybridization; Pulmonary fibrosis; Tissue factor

Indexed keywords

BLEOMYCIN; FIBRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; THROMBOPLASTIN; UROKINASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; IN SITU HYBRIDIZATION; LUNG ALVEOLUS; LUNG FIBROBLAST; LUNG INJURY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; BLEOMYCIN; DISEASE MODELS, ANIMAL; FEMALE; FIBRIN; FIBRINOLYSIS; GENE EXPRESSION; IN SITU HYBRIDIZATION; LUNG; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULMONARY FIBROSIS; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOPLASTIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029118192     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118201     Document Type: Article

References (66)

1. Burkhardt, A. 1989. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am. Rev. Respir. Dis. 140:513-524.
2. Crouch, E. 1990. Pathobiology of pulmonary fibrosis. Am. J. Physiol. 259:L159-L184.
3. Bowden, D. H. 1984. Unraveling pulmonary fibrosis: the bleomycin model. Lab. Invest. 50:487-488.
4. Janick-Buckner, D., G. E. Ranges, and M. P. Hacker. 1989. Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol. Appl. Pharmacol. 100:465-473.
5. Lindenschmidt, R. C., A. F. Tryka, G. A. Godfrey, E. L. Frome, and H. Witschi. 1986. Intratracheal versus intravenous administration of bleomycin in mice: acute effects. Toxicol. Appl. Pharmacol. 85:69-77.
6. Schrier, D. J., R. G. Kunkel, and S. H. Phan. 1983. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am. Rev. Respir. Dis. 127:63-66.
7. Brown, L. F., B. Asch, V. S. Harvey, B. Buchinski, and H. F. Dvorak. 1987. Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer. 1920-1925.
8. Dvorak, H. F., D. R. Senger, A. M. Dvorak, V. S. Harvey, and J. McDonaugh. 1985. Regulation of extravascular coagulation by microvascular permeability. Science (Wash. DC) 227:1059-1961.
9. Belew, M., B. Gerdin, J. Porath, and T. Saldeen. 1978. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb. Res. 13:983-994.
10. Skogen, W. F., R. M. Senior, G. L. Griffin, and G. D. Wilner. 1988. Fibrinogen-derived peptide Bβ1-42 is a multidomained neutrophil chemoattractant. Blood. 71:145-149.
11. Senior, R. M., W. F. Skogen, G. L. Griffin, and G. D. Wilner. 1986. Effects of fibrinogen derivatives upon the inflammatory response: studies with human nfibrinopeptide B. J. Clin. Invest. 77:1014-1019.
12. Bunce, L. A., L. A. Sporn, and C. W. Francis. 1992. Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the β chain. J. Clin. Invest. 89:842-850.
13. Limper, A. H., and J. Roman. 1992. A versatile matrix protein with roles in thoracic development, repair and infection. Chest. 101:1663-1673.
14. Kuhn, C., III, J. Boldt, T. E. King, Jr., E. Crouch, T. Vartio, and J. A. McDonald. 1989. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 140:1693-1703.
15. Drake, T. A., J. H. Morrissey, and T. S. Edgington. 1989. Selective cellular expression of tissue factor in human tissues. Am. J. Pathol. 134:1087-1097.
16. Edgington, T. S., N. Mackman, K. Brand, and W. Ruf. 1991. The structural biology of expression and function of tissue factor. Thromb. Haemostasis. 66:67-79.
17. McGee, M. P., and H. Rothberger. 1985. Tissue factor in bronchoalveolar lavage fluids. Am. Rev. Respir. Dis. 131:331-336.
18. Chapman, H. A., M. Stahl, C. L. Allen, R. Yee, and D. S. Fair. 1988. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am. Rev. Respir. Dis. 137:1417-1425.
19. Chapman, H. A., C. L. Allen, and O. L. Stone. 1986. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis. 133:437-444.
20. Blasi, F., J. Vassalli, and K. Dano. 1987. Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J. Cell Biol. 104:801-804.
21. Sappino, A. P., J. Huarte, J. D. Vassalli, and D. Belin. 1991. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Invest. 87:962-970.
22. Loskutoff, D. J., M. Sawdey, and J. Mimuro. 1988. Type 1 plasminogen activator inhibitor. In Progress in Hemostasis Thrombosis. B. Coller, editor. W. B. Saunders Co., Philadelphia. 87-115.
23. Vassalli, J., A. Sappino, and D. Belin. 1991. The plasminogen activator/ plasmin system. J. Clin. Invest. 88:1067-1072.
24. Sawdey, M., and D. J. Loskutoff. 1991. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J. Clin. Invest. 88:1346-1353.
25. Mackman, N., M. S. Sawdey, M. R. Keeton, and D. J. Loskutoff. 1993. Murine tissue factor gene expression in vivo: tissue and cell specificity and regulation by lipopolysaccharide. Am. J. Pathol. 143:76-84.
26. Idell, S., K. K. James, C. Gillies, D. S. Fair, and R. S. Thrall. 1989. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. Am. J. Pathol. 135:387-399.
27. Chapman, H. A., Jr., P. Bertozzi, and J. J. Reilly, Jr. 1988. Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest. 93:1256-1263.
28. Steinert, P. M., and D. R. Roop. 1988. Molecular and cellular biology of intermediate filaments. Annu. Rev. Biochem. 57:593-625.
29. Prendergast, G. C., L. E. Diamond, D. Dahl, and M. D. Cole. 1990. The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1. Mol. Cell. Biol. 10:1265-1269.
30. Mackman, N., S. Imes, W. H. Maske, B. Taylor, A. J. Lusis, and T. A. Drake. 1992. Structure of the murine tissue factor gene. Arterioscler. Thromb. 1:373-382.
31. Yun Tso, J., X. Sun, T. Kao, K. S. Reece, and R. Wu. 1985. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs:genomic complexity and molecular evolution of the gene. Nucleic Acids Res. 13:2485-2501.
32. Rickles, R. J., and S. Strickland. 1988. Tissue plasminogen activator mRNA in murine tissues. FEBS Lett. 229:100-106.
33. Keeton, M., Y. Eguchi, M. Sawdey, C. Ahn, and D. J. Loskutoff. 1993. Cellular localization of type 1 plasminogen activator inhibitor mRNA and protein in murine renal tissue. Am. J. Pathol. 142:59-70.
34. Olman, M. A., J. J. Marsh, I. M. Lang, K. M. Moser, B. R. Binder, and R. R. Schleef. 1992. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation. 86:1241-1248.
35. Erickson, L. A., D. A. Lawrence, and D. J. Loskutoff. 1984. Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 137:454-463.
36. Camiolo, S. M., M. R. Siuta, and J. M. Madeja. 1982. Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem. 12(4):297-305.
37. Bernik, M. B., and H. C. Kwaan. 1969. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J. Clin. Invest. 48:1740-1753.
38. Vassalli, J. D. and D. Belin. 1987. Amiloride selectively inhibits the urokinase-like plasminogen activator. FEBS Lett. 214:187-191.
39. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thyiocynate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
40. Schneiderman, J., M. S. Sawdey, M. R. Keeton, G. M. Bordin, E. F. Bernstein, R. B. Dilley, and D. J. Loskutoff. 1992. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA. 89:6998-7002.
41. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13.
42. Hoyt, D. G., and J. S. Lazo. 1988. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-β precede bleomycin-induced pulmonary fibrosis in mice. J. Pharmacol. Exp. Ther. 246:765-771.
43. Harpold, M. M. and R. M. Evans. 1979. Production of mRNA in chinese hamster cells: relationship of the rate of synthesis to the cytoplasmic concentration of none specific mRNA sequences. Cell. 1025-1035.
44. Zar, J. H. 1984. Biostatistical Analysis. Prentice-Hall, Inc. Englewood Cliffs, NJ. 718 pp.
45. Gurewich, V., and R. Pannell. 1987. Inactivation of single-chain urokinase (pro-urokinase ) by thrimbin and thriombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood. 69:769-772.
46. Woodcock-Mitchell, J., K. B. Adler, and R. B. Low. 1984. Immunohistochemical identification of cell types in normal and in bleomycin-induced fibrotic rat lung. Am. Rev. Respir. Dis. 130:910-916.
47. Sitrin, R., P. Brubaker, J. Shellito, and H. Kaltreider. 1986. The distribution of procoagulant and plasminogen activator activities among density fractions of normal rabbit alveolar macrophages. Am. Rev. Respir. Dis. 133:468-472.
48. Chapman, H., Jr., O. Stone, and Z. Vavrin. 1984. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. J. Clin. Invest. 73:806-815.
49. Idell, S., B. T. Peterson, K. K. Gonzalez, L. D. Gray, R. Bach, J. Mclarty, and D. S. Fair. 1988. Local abnormalities of coagulation and fibrinoloysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am. Rev. Respir. Dis. 138:1282-1294.
50. Idell, S., J. Peters, K. K. James, D. S. Fair, and J. J. Coalson. 1989. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J. Clin. Invest. 84:181-193.
51. Sitrin, R. G., P. G. Brubaker, and J. C. Fantone. 1987. Tissue fibrin deposition during acute lung injury in rabbits and its relationship to local expression of procoagulant and fibrinolytic activities. Am. Rev. Respir. Dis. 135:930-938.
52. Idell, S., K. K. James, E. G. Levin, B. S. Schwartz, N. Manchanda, R. J. Maunder, T. R. Martin, J. Mclarty, and D. S. Fair. 1989. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J. Clin. Invest. 84:695-705.
53. Gross, T. J., R. H. Simon, and R. G. Sitrin. 1992. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol. 6:397-403.
54. Drake, T., J. Cheng, A. Chang, and F. J. Taylor. 1993. Expression of tissue factor, thrombomodulin, and E-selectin baboons with lethal Escherechia coli sepsis. Am. J. Pathol. 142:1458-1470.
55. Aso, Y., K. Yoneda, and Y. Kirrawa. 1976. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab. Invest. 35:558-568.
56. Seiffert, D., and D. J. Loskutoff. 1991. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin Biochim. Biophys. Acta. 1078:23-30.
57. Liotta, L. A., R. H. Goldfarb, R. Brundage, G. P. Siegal, V. Terranova, and S. Garbisa. 1981. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41:4629-4636.
58. Sato, Y., and D. B. Rifkin. 1989. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-b-like molecule by plasmin during co-culture. J. Cell Biol. 109:309-315.
59. Laiho, M., O. Saksela, and J. Keski-Oja. 1987. Transforming growth factor-β induction of type 1 plasminogen activator inhibitor. J. Biol. Chem. 262:17467-17474.
60. Lund, L. R., A. Riccio, P. A. Andreasen, L. S. Nielsen, P. Kristensen, M. Laiho, O. Saksela, F. Blasi, and K. Dano. 1987. Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO (Eur. Mol. Biol. Org.) J. 6:1281-1286.
61. Ignotz, R. and J. Massague. 1986. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261:4337-4345.
62. Keski-Oja, J., R. Raghow, M. Sawdey, D. J. Loskutoff, A. E. Postlethwaite, A. H. Kang, and H. L. Moses. 1988. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type 1 pro collagen by transforming growth factor-β. J. Biol. Chem. 263:3111-3115.
63. Ignotz, R. A., T. Endo, and J. Massague. 1987. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J. Biol. Chem. 262:6443-6446.
64. Broekelmann, T. J., A. H. Limper, T. V. Colby, and J. A. McDonald. 1991. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 88:6642-6646.
65. Khalil, N., O. Bereznay, M. Sporn, and A. H. Greenberg. 1989. Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J. Exp. Med. 170:727-737.
66. Raghow, R., S. Lurie, J. M. Seyer, and A. H. Kang. 1985. Profiles of steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J. Clin. Invest. 76:1733-1739.